{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:49:52Z","timestamp":1784198992437,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81904290"],"award-info":[{"award-number":["81904290"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Research & Clinical Practice"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.orcp.2025.11.005","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T05:46:23Z","timestamp":1764827183000},"page":"536-543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Signal identification of adverse reactions related to phentermine\/topiramate: A study based on FAERS reports"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0841-2073","authenticated-orcid":false,"given":"Xinyue","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianhong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihan","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqian","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.orcp.2025.11.005_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2022-009773","article-title":"Economic impacts of overweight and obesity: current and future estimates for 161 countries","volume":"7","author":"Okunogbe","year":"2022","journal-title":"BMJ Glob Health"},{"issue":"17","key":"10.1016\/j.orcp.2025.11.005_bib2","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1001\/jama.2024.17533","article-title":"Lifestyle interventions for obesity","volume":"332","author":"Davis","year":"2024","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.orcp.2025.11.005_bib3","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/jama.2020.12567","article-title":"Benefits and risks of bariatric surgery in adults: a review","volume":"324","author":"Arterburn","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.orcp.2025.11.005_bib4","unstructured":"Halpern B., Mancini M.C. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone\/bupropion extended release and phentermine-topiramate extended release. Expert Opinion on Drug Safety. Published online January 2, 2017. Accessed January 24, 2025. \u3008https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/14740338.2017.1247807\u3009."},{"key":"10.1016\/j.orcp.2025.11.005_bib5","first-page":"267","article-title":"Phentermine and topiramate for the management of obesity: a review","volume":"7","author":"Cosentino","year":"2013","journal-title":"Drug Des Devel Ther"},{"issue":"S1","key":"10.1016\/j.orcp.2025.11.005_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1157.2000.tb02163.x","article-title":"An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action","volume":"41","author":"Shank","year":"2000","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.orcp.2025.11.005_bib7","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s40265-018-0946-y","article-title":"Centrally acting drugs for obesity: past, present, and future","volume":"78","author":"Coulter","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.orcp.2025.11.005_bib8","unstructured":"QSYMIA (phentermine and topiramate extended-release capsules)package insert."},{"issue":"3","key":"10.1016\/j.orcp.2025.11.005_bib9","first-page":"420","article-title":"A standardized dataset of a spontaneous adverse event reporting system","volume":"10","author":"Khaleel","year":"2022","journal-title":"Healthc (Basel)"},{"issue":"6","key":"10.1016\/j.orcp.2025.11.005_bib10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17425255.2023.2235267","article-title":"A real-world data analysis of acetylsalicylic acid in FDA adverse event reporting system (FAERS) database","volume":"19","author":"Zhao","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"10.1016\/j.orcp.2025.11.005_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/17425255.2023.2219390","article-title":"A real-world data analysis of topotecan in the FDA adverse event reporting system (FAERS) database","volume":"19","author":"Yang","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.orcp.2025.11.005_bib12","article-title":"A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Pharm"},{"issue":"4","key":"10.1016\/j.orcp.2025.11.005_bib13","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/andr.13533","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil","volume":"12","author":"Wang","year":"2024","journal-title":"Andrology"},{"issue":"11","key":"10.1016\/j.orcp.2025.11.005_bib14","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1080\/14740338.2024.2410436","article-title":"A real-world pharmacovigilance study using disproportionality analysis of United States food and drug administration adverse event reporting system events for vinca alkaloids: comparing vinorelbine and Vincristine","volume":"23","author":"Zhong","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.orcp.2025.11.005_bib15","article-title":"Vitreoretinal traction syndrome, nitrituria and human epidermal growth factor receptor negative might occur in the aromatase-inhibitor anastrozole treatment","volume":"2024","author":"Li","year":"2024","journal-title":"Int J Clin Pract"},{"issue":"8","key":"10.1016\/j.orcp.2025.11.005_bib16","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf"},{"key":"10.1016\/j.orcp.2025.11.005_bib17","doi-asserted-by":"crossref","unstructured":"Dumouchel W. Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System. The American Statistician. Published online August 1, 1999. Accessed February 5, 2025. \u3008https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/00031305.1999.10474456\u3009.","DOI":"10.2307\/2686097"},{"issue":"6","key":"10.1016\/j.orcp.2025.11.005_bib18","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"10.1016\/j.orcp.2025.11.005_bib19","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.orcp.2025.11.005_bib20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12959-025-00770-4","article-title":"Thromboembolic events associated with angiogenesis inhibitors: a real-world study of data from the food and drug administration adverse event reporting system (FAERS) database","volume":"23","author":"Zhou","year":"2025","journal-title":"Thromb J"},{"key":"10.1016\/j.orcp.2025.11.005_bib21","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40264-023-01306-3","article-title":"Identifying safety subgroups at risk: assessing the agreement between statistical alerting and patient subgroup risk","volume":"46","author":"Mahaux","year":"2023","journal-title":"Drug Saf"},{"issue":"15","key":"10.1016\/j.orcp.2025.11.005_bib22","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.2165\/11640860-000000000-00000","article-title":"Phentermine and topiramate extended release (Qsymia\u2122): first global approval","volume":"72","author":"Cameron","year":"2012","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.orcp.2025.11.005_bib23","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s13679-021-00453-x","article-title":"Sex\/gender differences in obesity prevalence, comorbidities, and treatment","volume":"10","author":"Cooper","year":"2021","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.orcp.2025.11.005_bib24","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s11096-021-01330-2","article-title":"Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA adverse event reporting system (FAERS) databases 2013\u20132020","volume":"44","author":"Alsuhibani","year":"2021","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.orcp.2025.11.005_bib25","article-title":"Is the weight loss medication phentermine\/topiramate safe in obese adult patients with hypertension?","author":"Davis","year":"2019","journal-title":"EvidBased Pract"},{"key":"10.1016\/j.orcp.2025.11.005_bib26","doi-asserted-by":"crossref","unstructured":"Mechrgui M., Kanani S. The Ophthalmic Side Effects of Topiramate: A Review. Cureus. 14(8):e28513. doi:10.7759\/cureus.28513.","DOI":"10.7759\/cureus.28513"},{"key":"10.1016\/j.orcp.2025.11.005_bib27","unstructured":"Adipex-P\u00ae [package insert] Sellersville, PA: Teva Pharmaceuticals, USA; 2012."},{"issue":"4","key":"10.1016\/j.orcp.2025.11.005_bib28","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/jebm.12667","article-title":"Postmarketing safety surveillance of topiramate: a signal detection and analysis study based on the FDA adverse event reporting system database","volume":"17","author":"Lin","year":"2024","journal-title":"J Evid Based Med"},{"issue":"4","key":"10.1016\/j.orcp.2025.11.005_bib29","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/AOG.0000000000004697","article-title":"Effect of topiramate on serum etonogestrel concentrations among contraceptive implant users","volume":"139","author":"Lazorwitz","year":"2022","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.orcp.2025.11.005_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.reprotox.2024.108601","article-title":"Topiramate treatment during adolescence induces short and long-term alterations in the reproductive system of female rats","volume":"126","author":"Bilibio","year":"2024","journal-title":"Reprod Toxicol"},{"issue":"5","key":"10.1016\/j.orcp.2025.11.005_bib31","doi-asserted-by":"crossref","first-page":"499","DOI":"10.12891\/ceog16592014","article-title":"Association of sympathetic nervous system activity with polycystic ovarian syndrome","volume":"41","author":"Li","year":"2014","journal-title":"Clin Exp Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.orcp.2025.11.005_bib32","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/157488609789007001","article-title":"A case of topiramate-induced epistaxis","volume":"4","author":"Polimeni","year":"2009","journal-title":"Curr Drug Saf"},{"issue":"8","key":"10.1016\/j.orcp.2025.11.005_bib33","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jocn.2015.02.009","article-title":"Paradoxical topiramate-induced hyperphagia successfully treated with phentermine in a woman with migraine","volume":"22","author":"Johnson","year":"2015","journal-title":"J Clin Neurosci"},{"issue":"11","key":"10.1016\/j.orcp.2025.11.005_bib34","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.3390\/nu9111274","article-title":"Emotion regulation in binge eating disorder: a review","volume":"9","author":"Dingemans","year":"2017","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.orcp.2025.11.005_bib35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1172\/JCI108460","article-title":"The role of adrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia in man","volume":"58","author":"Garber","year":"1976","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.orcp.2025.11.005_bib36","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1530\/EJE-12-0500","article-title":"Short-term topiramate treatment does not improve insulin sensitivity or secretion in obese insulin-resistant women","volume":"167","author":"Sleddering","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"10.1016\/j.orcp.2025.11.005_bib37","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.clineuro.2012.01.025","article-title":"Topiramate and erectile dysfunction: pathogenic mechanisms beyond sexual hormonal changes!","volume":"114","author":"Calabr\u00f2","year":"2012","journal-title":"Clin Neurol Neurosurg"}],"container-title":["Obesity Research & Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871403X2500136X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871403X2500136X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:35:43Z","timestamp":1773873343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871403X2500136X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1871403X2500136X"],"URL":"https:\/\/doi.org\/10.1016\/j.orcp.2025.11.005","relation":{},"ISSN":["1871-403X"],"issn-type":[{"value":"1871-403X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Signal identification of adverse reactions related to phentermine\/topiramate: A study based on FAERS reports","name":"articletitle","label":"Article Title"},{"value":"Obesity Research & Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.orcp.2025.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Asia Oceania Association for the Study of Obesity. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}